Evidence map›Paper›PMID 40038310›Full record

ArticleNature communications2025

Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumors.

Céline Patte, Roxane M Pommier, Anthony Ferrari, Felicia Fei-Lei Chung, Maria Ouzounova, Pauline Moullé, Mathieu Richaud, Rita Khoueiry, Maëva Hervieu, Silvia Breusa and 19 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Spatial Transcriptomics Reveals Location-Specific Tumor Cell Subtypes and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Novel concepts of cell-of origin in neuroendocrine neoplasms.Virchows Archiv : an international journal of pathology · 2026
    Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Céline Patte *Gastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-3292-5628
Roxane M Pommier *Plateforme Bioinformatique Gilles Thomas, Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-5351-7367
Anthony Ferrari *Plateforme Bioinformatique Gilles Thomas, Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France.
Felicia Fei-Lei Chung *Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France.ORCID http://orcid.org/0000-0003-1043-4948
Maria OuzounovaGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0001-8934-3461
Pauline MoulléGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Mathieu RichaudGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0002-7472-9019
Rita KhoueiryEpigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France.
Maëva HervieuGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Silvia BreusaGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Marion AllioGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Nicolas RamaApoptosis, Cancer and Development (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-1614-7755
Laura GérardGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Valérie HervieuGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Gilles PoncetHospices Civils de Lyon, Hôpital Edouard Herriot, Service de Chirurgie Digestive, Lyon, France.
Tanguy FenouilGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Vincent CahaisEpigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France.
Anne-Sophie SertierPlateforme Bioinformatique Gilles Thomas, Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France.
Anne BolandUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.ORCID http://orcid.org/0000-0001-8789-5676
Delphine Bacq-DaianUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.ORCID http://orcid.org/0000-0002-6965-8244
Benjamin DucarougeNetris Pharma, Lyon, France.ORCID http://orcid.org/0000-0002-6701-0508
Julien C MarieTGF-beta and Immune Response (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Equipe labellisée Ligue nationale contre le cancer, Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0001-6713-7923
Jean-François DeleuzeUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France.ORCID http://orcid.org/0000-0002-5358-4463
Alain ViariPlateforme Bioinformatique Gilles Thomas, Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France.
Jean-Yves ScoazecDepartment of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0003-1604-6823
Colette RocheGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.
Patrick MehlenApoptosis, Cancer and Development (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France.ORCID http://orcid.org/0000-0003-1743-5417
Thomas WalterGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France. thomas.walter@chu-lyon.fr.ORCID http://orcid.org/0000-0002-4199-4561
Benjamin GibertGastroenterology and technologies for health (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Cancer Research Center of Lyon, Lyon, France. benjamin.gibert@lyon.unicancer.fr.ORCID http://orcid.org/0000-0002-5295-3124

Funding

World Health Organization 001
6 · The paper itself

Abstract

Small intestinal neuroendocrine tumors (siNETs) are rare bowel tumors arising from malignant enteroendocrine cells, which normally regulate digestion throughout the intestine. Though infrequent, their incidence is rising through better diagnosis, fostering research into their origin and treatment. To date, siNETs are considered to be a single entity and are clinically treated as such. Here, by performing a multi-omics analysis of siNETs, we unveil four distinct molecular groups with strong clinical relevance and provide a resource to study their origin and clinical features. Transcriptomic, genetic and DNA methylation profiles identify two groups linked to distinct enteroendocrine differentiation patterns, another with a strong immune phenotype, and the last with mesenchymal properties. This latter subtype displays the worst prognosis and resistance to treatments in line with infiltration of cancer-associated fibroblasts. These data provide insights into the origin and diversity of these rare diseases, in the hope of improving clinical research into their management.

Indexed as

Genetic VariationIntestinal NeoplasmsIntestine, SmallNeuroendocrine TumorsDNA MethylationEnteroendocrine CellsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptome

Identifiers

PMID40038310
PMCPMC11880452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.